Moderna Likely To Report Q4 Loss; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Portfolio Pulse from Avi Kapoor
Moderna, Inc. (NASDAQ:MRNA) is anticipated to report a Q4 loss with earnings expected at 97 cents per share compared to $3.61 per share a year ago, and revenue projected at $2.5 billion versus $5.08 billion in the previous year. The company announced updates at the JPMorgan Healthcare Conference, highlighting 45 therapeutic and vaccine programs, with nine in late-stage development. Analysts have provided mixed ratings, with price targets ranging from $82 to $142.
February 22, 2024 | 7:32 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Moderna is projected to report a significant Q4 loss with lower earnings and revenue compared to the previous year. Analyst ratings and price targets show a mixed outlook, with some optimism reflected in recent upgrades.
The expected Q4 loss and reduced revenue projection indicate a short-term negative impact. However, the mixed analyst ratings, including a notable upgrade from Oppenheimer, suggest uncertainty in the stock's short-term direction. The company's announcement of progress in its pipeline could provide some positive sentiment.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100